Friday - December 15, 2017
Experimental Treatment for Niemann-Pick Disease Type C1 Appears Safe, Effective
August 11, 2017
BETHESDA, Md., Aug. 11 -- The National Institutes of Health's National Institute on Deafness and Other Communication Disorders issued the following news:

An experimental drug appears to slow the progression of Niemann-Pick disease type C1 (NPC1), a fatal neurological disease, according to results of a clinical study led by researchers at the National Institutes of Health. The study appears in The Lancet.

NPC1 is a rare genetic disorder that primarily affects children an . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

What's your
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products